ALNYLAM PHARMACEUTICALS, INC. (ALNY) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-07

Key Insights

The reporting person, Melissa McLaughlin, Chief Human Resources Officer at Alnylam Pharmaceuticals, has sold a substantial number of Alnylam shares on the open market over the past few days, totaling over 2,500 shares.
The sales were made pursuant to a pre-established 10b5-1 trading plan, suggesting the transactions were part of a planned strategy rather than discretionary selling.
The trading volume and timing of the sales may be of interest to investors as it could signal the reporting person's views on the company's near-term prospects or their personal financial planning.

Want the newest filings?

This analysis covers the filing from 2026-04-07. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-06

The reporting person, Kevin Joseph Fitzgerald, sold a total of 1,205 shares of Alnylam Pharmaceuticals, Inc. (ALNY) common stock on March 4 and 5, 2026, likely to cover tax withholding obligations on the vesting of restricted stock units.
The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, indicating pre-planned transactions rather than discretionary selling.
The reporting person continues to hold a substantial position of 21,227 shares of ALNY common stock following the reported transactions, suggesting ongoing confidence in the company.

Filed: 2026-03-06

Tolga Tanguler, the EVP and Chief Commercial Officer of Alnylam Pharmaceuticals, sold 2,109 shares of the company's common stock on March 4, 2026 at prices ranging from $319.03 to $326.21.
The sales were made pursuant to a mandatory sell-to-cover provision in Tanguler's award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.
Following the reported transactions, Tanguler's beneficial ownership of Alnylam's common stock decreased from 36,500 shares to 34,297 shares.

Filed: 2026-03-06

The filing indicates that Jeffrey V. Poulton, the EVP and Chief Financial Officer of Alnylam Pharmaceuticals, Inc. (ALNY), has sold a significant number of shares on March 4, 2026, totaling 2,248 shares at prices ranging from $319.03 to $326.21.
The share sales appear to be part of a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units, rather than a discretionary sale.
The reporting person still holds a substantial number of shares (61,862) after the reported transactions, suggesting they maintain a significant ownership stake in the company.

Filed: 2026-03-06

Yvonne Greenstreet, the CEO of Alnylam Pharmaceuticals, made a series of stock sales on March 4, 2026 to cover tax withholding obligations on vesting of restricted stock units.
The sales were made in multiple transactions at prices ranging from $318.27 to $326.21, with a total of 2,933 shares sold.
The CEO still holds a significant stake of 95,695 shares in the company, indicating ongoing commitment despite the stock sales.

Filed: 2026-03-06

Insider Garg Pushkal, EVP Chief R&D, has sold a significant amount of Alnylam Pharmaceuticals (ALNY) shares over the past two trading days, totaling 6,207 shares.
The sales appear to be automatic sell-to-cover transactions to cover tax withholding obligations upon the vesting of restricted stock units, rather than open market sales.
The trading activity suggests Garg may have confidence in the near-term performance of Alnylam's stock price, as the sales were made at prices above $318 per share.

Filed: 2026-01-14

The reporting person, Kevin Joseph Fitzgerald, who is the Chief Scientific Officer and Executive Vice President, Head of Research at Alnylam Pharmaceuticals, Inc., received 3,800 shares of common stock upon vesting of a performance-based stock unit (PSU) award.
Fitzgerald subsequently sold a total of 1,522 shares of common stock over multiple transactions on January 12 and 13, 2026, at prices ranging from $353.95 to $377.82.
The reported transactions suggest that Fitzgerald is actively managing his equity holdings in the company, potentially to diversify his portfolio or meet personal financial obligations.

Filed: 2026-01-14

The reporting person, Tolga Tanguler, EVP and Chief Commercial Officer of Alnylam Pharmaceuticals, acquired 3,800 shares of the company's common stock on January 11, 2026, which suggests his confidence in the company's performance.
Tanguler subsequently sold a total of 1,045 shares of Alnylam's common stock on January 12, 2026, potentially to cover tax withholding obligations related to the equity award.
The insider trading activity indicates a mix of positive and neutral sentiment, as the initial acquisition suggests a bullish outlook, while the subsequent sales may be routine in nature.

Filed: 2026-01-14

The reporting person, Jeffrey V. Poulton, who is the EVP and Chief Financial Officer of Alnylam Pharmaceuticals, Inc. (ALNY), acquired 6,193 shares of ALNY common stock on January 11, 2026 as part of a performance-based stock unit (PSU) award that vested.
Poulton subsequently sold a total of 1,760 shares of ALNY stock on January 12, 2026 through multiple transactions at prices ranging from $353.95 to $377.82, likely to cover tax withholding obligations.
After the reported transactions, Poulton continues to hold a substantial direct ownership position of 57,492 shares of ALNY common stock, indicating his alignment with and confidence in the company's long-term prospects.

Filed: 2026-01-14

The reporting person, Yvonne Greenstreet, who is the CEO of Alnylam Pharmaceuticals, Inc., acquired 19,003 shares of common stock through a performance-based stock unit (PSU) award that vested based on the company achieving a financial milestone.
Greenstreet subsequently sold a total of 6,763 shares of common stock over multiple transactions on January 12, 2026, likely to cover tax withholding obligations related to the vesting of the PSU.
The insider selling appears to be routine and not indicative of a significant change in Greenstreet's overall ownership or sentiment towards the company, as she still holds over 78,000 shares of common stock.

Filed: 2026-01-14

The reporting person, Pushkal Garg, who is the EVP Chief R&D of Alnylam Pharmaceuticals, Inc. (ALNY), was granted 3,800 shares of common stock upon the vesting of a performance-based stock unit (PSU) award.
Garg subsequently sold a total of 1,059 shares of ALNY common stock in multiple transactions on January 12, 2026, with the sales prices ranging from $353.95 to $377.82 per share.
After the reported transactions, Garg continues to beneficially own 22,511 shares of ALNY common stock, along with an additional 431 shares held indirectly through a managed account and 250 shares held indirectly through a trust.

Filed: 2026-01-07

Insider Stuart A. Arbuckle acquired 3,279 stock options of Alnylam Pharmaceuticals, Inc. (ALNY) on January 5, 2026, indicating potential confidence in the company's future prospects.
The stock options have a 10-year expiration and will vest in three equal installments on the first, second, and third anniversaries of the grant date, aligning Arbuckle's interests with long-term shareholders.
The transaction suggests Arbuckle, a director at Alnylam, believes the company's stock has room for growth, and he is willing to invest in the company's future performance.

Other reports for ALNYLAM PHARMACEUTICALS, INC.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.